Reuters logo
TEXT - S&P comments on Centene Corp
November 5, 2012 / 6:59 PM / in 5 years

TEXT - S&P comments on Centene Corp

Nov 5 - As Standard & Poor's Ratings Services previously announced, its 'BB'
rating on Centene Corp.'s $250 million senior unsecured notes maturing June 1,
2017, remains unchanged after the company issued a $150 million add-on to the

The company will use the proceeds of the notes for general corporate purposes, 
including funding statutory surplus at its operating subsidiaries to support 
business growth.

We believe that Centene has a good competitive position in the managed 
Medicaid market with a growing presence in this market segment, which helps to 
mitigate its relatively narrow market-segment focus on government-sponsored 
managed Medicaid programs. We expect the company to continue to grow and 
generate stable cash flow in the intermediate term (12 to 24 months) to meet 
its debt-service requirements and pay for expenses related to expansion into 
new markets.

However, our counterparty credit rating on Centene is constrained by the 
concentration of its revenue stream in the government-sponsored managed 
Medicaid programs, with a smaller percentage of premiums coming from specialty 
services from external customers. This narrow market focus is a key credit 
risk, as it exposes the company to adverse regulatory and legislative 
developments. Accordingly, profitability and sustained revenue growth depend 
heavily on continued government funding for these programs to keep pace with 
medical cost trends.

We expect Centene's key holding-company credit metrics to remain consistent 
with the current rating level. At year-end 2012 we expect its debt-to-capital 
ratio to be in the 30%-35% range (excluding the mortgage note and including 
operating lease obligation treated as debt), up from 26.5% as of year-end 
2011. In our calculation of 2012 EBIT ROR and EBITDA we adjust for certain 
one-time items including the premium deficiency reserve for its Kentucky 
Health Plan and goodwill and intangible write-down related to its Celtic 
subsidiary. We expect adjusted EBITDA interest coverage in 2012-2013 to be 
more than 7x. We expect risk-adjusted capitalization to remain redundant at 
the 'BBB' level per our capital model. For 2012 we expect adjusted EBIT ROR to 
be in the 2% range and to improve in 2013 to the 2%-3% range. EBIT ROR for 
2012 reflects higher-than-expected medical costs in its Kentucky Health Plan 
and the Hidalgo service area in its Texas Health Plan, as well as in the 
Celtic individual health business.

We expect premium rate increases in its Texas Health Plan and the planned exit 
from Kentucky to improve operating results in 2013.

Holding Company Analysis, June 11, 2009

Ratings List
Centene Corp.
Counterparty Credit Rating     BB/Negative/--
Sr. Unsec. Debt Due 2017       BB

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below